Press release
Atopic Dermatitis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Scie
Atopic Dermatitis Pipeline Analysis by DelveInsight
Atopic Dermatitis Overview:
Atopic Dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition and the most prevalent form of skin inflammation. While it often begins in early childhood, it can occur at any age and may be recurrent or persist throughout life. The term "dermatitis" comes from "derm" meaning skin and "itis" meaning inflammation. AD is characterized by dryness, itching, redness, and rash, often caused by a combination of genetic predisposition, immune system overactivity, allergies, infections, and irritants. Around half of individuals with moderate-to-severe eczema also experience asthma, hay fever, or food allergies. It is the most common chronic skin condition in children.
The hallmark symptom is dry, itchy skin that can progress into a red rash during flare-ups. Various environmental and internal triggers can set off these flares, leading to inflammation, increased blood flow, and intense itching. This contributes to the itch-scratch cycle, which worsens inflammation and may cause skin thickening (lichenification) and discoloration. Persistent scratching can also result in skin infections.
The pathophysiology of AD is complex and involves multiple factors, including skin barrier dysfunction, immune system dysregulation, IgE-mediated hypersensitivity, and environmental triggers. Mutations in the filaggrin gene have been linked to severe AD, as they can increase transepidermal water loss, alter skin pH, and cause dehydration. Other genetic variations affecting skin barrier function may also contribute to the AD phenotype. An imbalance in Th2 and Th1 cytokines can alter cell-mediated immune responses and promote IgE-mediated hypersensitivity. Eczema often features spongiosis, allowing inflammatory mediators to accumulate. Additionally, dendritic cell subtypes-such as Langerhans cells, inflammatory dendritic epidermal cells, and plasmacytoid dendritic cells-play a significant role in disease development.
Request for a detailed insights report on Atopic Dermatitis pipeline insights https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Atopic Dermatitis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Atopic Dermatitis Therapeutics Market.
Key Takeaways from the Atopic Dermatitis Pipeline Report
DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Atopic Dermatitis treatment.
The FDA approved this once-daily, steroid-free topical in July 2024 for mild to moderate AD in patients aged 6 and older. It offers rapid itch relief and sustained disease control with application anywhere on the body-including sensitive areas
In December 2024, the FDA approved this aryl hydrocarbon receptor agonist for treating AD in patients 2 years and older. Clinical trials showed quick itch improvement (within 24 hours) and significant skin clearance by week 8, with many patients remaining treatment-free for around 80 days
Key Atopic Dermatitis companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics, and others are evaluating new drugs for Atopic Dermatitis to improve the treatment landscape.
Promising Atopic Dermatitis pipeline therapies in various stages of development include ICP-332, APG777, Barzolvolimab, ATI-2138, STAR-0310, and others.
Atopic Dermatitis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Atopic Dermatitis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Atopic Dermatitis market.
Download our free sample page report on Atopic Dermatitis pipeline insights https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Atopic Dermatitis Emerging Drugs
ICP-332 - Innocare Pharma
ICP-332 is a highly potent and selective TYK2 inhibitor in development for treating a range of T-cell-mediated autoimmune disorders, such as atopic dermatitis (AD), vitiligo, and inflammatory bowel disease, offering broad market potential. TYK2, a non-receptor tyrosine kinase belonging to the JAK kinase family, plays a critical role in the JAK-STAT signaling pathway and is closely linked to the development of inflammatory diseases. ICP-332 is currently in Phase III clinical trials for AD.
APG777 - Apogee Therapeutics
APG777 is an innovative subcutaneous monoclonal antibody with extended half-life, designed to target IL-13 for the treatment of AD. In comparative preclinical studies, it demonstrated equal or greater potency than lebrikizumab in inhibiting IL-13 signaling. Phase 1 clinical data over 12 months revealed a half-life of 77 days, a favorable safety and pharmacodynamic profile, near-complete inhibition of pSTAT6 for up to a year after a single dose, and sustained suppression of TARC. APG777 is currently undergoing Phase II clinical trials for AD.
Atopic Dermatitis Companies
There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. Phase III include, Innocare Pharma.
DelveInsight's report covers around 75+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Atopic Dermatitis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Atopic Dermatitis Therapies and Key Companies: Atopic Dermatitis Clinical Trials and advancements https://www.delveinsight.com/report-store/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Atopic Dermatitis Pipeline Therapeutic Assessment
• Atopic Dermatitis Assessment by Product Type
• Atopic Dermatitis By Stage
• Atopic Dermatitis Assessment by Route of Administration
• Atopic Dermatitis Assessment by Molecule Type
Download Atopic Dermatitis Sample report to know in detail about the Atopic Dermatitis treatment market @ Atopic Dermatitis Therapeutic Assessment https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Atopic Dermatitis Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Scie here
News-ID: 4144358 • Views: …
More Releases from DelveInsight Business Research LLP
Electrical Stimulation Devices Market Poised for Steady Growth, Fueled by Innova …
The global functional electrical stimulation (FES) devices market is projected to grow at a CAGR of 8.2% from 2024 to 2030. Growth is mainly driven by the increasing prevalence of musculoskeletal disorders worldwide, along with the growing emphasis on pain management therapies and continuous technological advancements in product development, which are expected to further boost the market in the coming years.
DelveInsight's Electrical Stimulation Devices Market Insights report provides the current…
Brain Monitoring Devices Market Poised for Steady Growth, Fueled by Innovation a …
The brain monitoring devices market, valued at USD 5.89 billion in 2023, is projected to grow at a CAGR of 7.27% from 2024 to 2030, reaching USD 9.13 billion by 2030. Growth is driven by the rising prevalence of neurological disorders such as multiple sclerosis, epilepsy, and dementia, along with increasing awareness and ongoing product development activities, all contributing to the market's expansion during the forecast period.
DelveInsight's Brain Monitoring Devices…
Sleep Apnea Devices Market Poised for Steady Growth, Fueled by Innovation and Ri …
The global sleep apnea devices market, valued at USD 7.53 billion in 2023, is projected to grow at a CAGR of 6.26% from 2024 to 2030, reaching USD 10.82 billion by 2030. Growth is driven by the rising prevalence of sleep apnea, increasing obesity rates, and greater adoption of advanced technologies. Additional factors such as heightened awareness, a growing elderly population, and a surge in product launches and approvals are…
Hypertriglyceridemia Clinical, Companies, Therapeutic Assessment, Therapies, Tre …
Hypertriglyceridemia Pipeline constitutes 18+ key companies continuously working towards developing 20+ Hypertriglyceridemia treatment therapies, analyzes DelveInsight.
Hypertriglyceridemia Overview:
Hypertriglyceridemia is a condition marked by high triglyceride levels in the blood, which can increase the risk of cardiovascular disease (CVD) and acute pancreatitis. It is commonly linked to factors such as uncontrolled diabetes, obesity, physical inactivity, and genetics. Typically, the condition remains without symptoms until triglyceride levels surpass 1,000-2,000 mg/dL, at which point…
More Releases for Atopic
Atopic Dermatitis Market Trends That Will Shape the Next Decade: Insights from P …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
How Large Will the Atopic Dermatitis Market Size By 2025?
The market size for atopic dermatitis has seen significant expansion in the past few years. This expansion is anticipated to continue, with the market size increasing from $8.61 billion in 2024 to $9.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of…
Atopic Dermatitis Pipeline Outlook Report 2024
DelveInsight's, "Atopic Dermatitis Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline…
Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects
The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.
Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result…
Atopic Dermatitis - Drug Pipeline Landscape, 2023
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may crak and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger…
Atopic Dermatitis - Drug Pipeline Landscape, 2022
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may cr*ck and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness.
Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an…
Atopic Dermatitis (Atopic Eczema) Treatment Market Business Growth And Industry …
Precision Business Insights published a research report on “Atopic Dermatitis (Atopic Eczema) Treatment Market by Drug type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), Route of administration (Oral, Topical, Parenteral), Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography - Global/Region/Country Forecast to 2027”.
In people who suffer from atopic dermatitis, allergies play a big influence. When the patient is exposed to…
